Established in 2016 in Oxfordshire, the pharmaceutical company Emergex has secured approval from the Swiss regulator to conduct tests of the new vaccine on 26 people in Lausanne from January 3, 2022. Preliminary results are expected in June next year.
Innovative preparation may be available from 2025, according to the standard, not according to the accelerated preparation work schedule. The crisis situation is over, said Robert Cohen, Emergex’s commercial director, which has increased the pace as part of the regulatory process to bring currently available vaccines to market.
The virus is like a meteor that slammed into a planet. The viral code, a type of virus signature, is rapidly projected over the entire surface of the attacking organism. T cells read the codes as foreign. Therefore, the captured cell becomes harmless before new live viruses can replicate in it, Cohen added.
Danny Altman, professor of immunology at Imperial College London, said he doubted the T-cell vaccine “can do the job on its own”, but believed it could play a complementary role in the vaccine blending approach.
A human thumb-sized patch, filled with fine needles, is designed to release the formula within a few seconds. It can be stored at room temperature for up to several months.
Emergex is also testing T-cell vaccines against dengue fever, which, according to the World Health Organization, is at risk for half the world’s population. To date, no medicinal preparations or preparations have been developed that protect against infection with the virus of this disease.
The mode of action of T lymphocytes is also used to develop vaccines against Ebola, Zika virus, and seasonal influenza.
Date created: Today 10:25
“Infuriatingly humble musicaholic. Problem solver. Reader. Hardcore writer. Alcohol evangelist.”